I agree that this site is using cookies. You can find further informations here.
X
Lakhani, N.J.
301  results:
Search for persons X
?
1

A first-in-human phase I study of the PD-1 inhibitor, retif..:

Lakhani, N. ; Cosman, R. ; Banerji, U....
ESMO Open.  9 (2024)  4 - p. 102254 , 2024
Link: https://doi.org/10.1016/..
 
?
2

A Phase 1 study of fianlimab in combination with cemiplimab..:

Kaczmar, J. ; Papadopoulos, K. ; Ansstas, G....
EJC Skin Cancer.  2 (2024)  - p. 100213 , 2024
Link: https://doi.org/10.1016/..
 
?
3

44O Updated results from a phase I study evaluating the KRA..:

Rojas, C.I. ; Lugowska, I. ; Juergens, R....
ESMO Open.  9 (2024)  - p. 102273 , 2024
Link: https://doi.org/10.1016/..
 
?
4

Ongoing phase II study of EZH2 inhibitor CPI-0209 in patien..:

Kwiatek, M. ; Gutierrez, M. ; Harvey, R.D....
European Urology.  83 (2023)  - p. S758-S759 , 2023
Link: https://doi.org/10.1016/..
 
?
5

Establishment and characterization of a panel of BRAFV600E ..:

Moriarty, A. ; Flores, J. ; Peskin, A....
European Journal of Cancer.  174 (2022)  - p. S14 , 2022
Link: https://doi.org/10.1016/..
 
?
6

196TiP A phase I study of REGN6569, a GITR monoclonal antib..:

Lakhani, N. ; Hamid, O. ; Braña, I....
Immuno-Oncology and Technology.  16 (2022)  - p. 100308 , 2022
Link: https://doi.org/10.1016/..
 
?
7

150P Phase I study of fianlimab: A human lymphocyte activat..:

Hamid, O. ; Lewis, K. ; Weise, A....
Immuno-Oncology and Technology.  16 (2022)  - p. 100262 , 2022
Link: https://doi.org/10.1016/..
 
?
8

A first-in-human study of the anti-LAG-3 antibody favezelim..:

Garralda, E. ; Sukari, A. ; Lakhani, N.J....
ESMO Open.  7 (2022)  6 - p. 100639 , 2022
Link: https://doi.org/10.1016/..
 
?
9

172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, ..:

Papadopoulos, K. ; Li, T. ; Lakhani, N....
Immuno-Oncology and Technology.  16 (2022)  - p. 100284 , 2022
Link: https://doi.org/10.1016/..
 
?
10

Phase I, first-in-human study of MSC-1 (AZD0171), a humaniz..:

Borazanci, E. ; Schram, A.M. ; Garralda, E....
ESMO Open.  7 (2022)  4 - p. 100530 , 2022
Link: https://doi.org/10.1016/..
 
?
11

Efficacy signals, long-term exposure and safety data from a..:

Fontana, E. ; Williams, A. ; Falchook, G....
European Journal of Cancer.  174 (2022)  - p. S82-S83 , 2022
Link: https://doi.org/10.1016/..
 
?
12

Identification and molecular characterization of invasive l..:

Flores, J. ; Moriarty, A. ; Lizette, F....
European Journal of Cancer.  174 (2022)  - p. S121 , 2022
Link: https://doi.org/10.1016/..
 
?
13

The African Vaccine-Preventable Diseases Network: a vaccine..:

Wiysonge, CS ; Armah, GE ; Madhi, SA...
Pan African Medical Journal.  8 (2011)  1 - p. , 2011
Link: https://doi.org/10.4314/..
 
?
14

A cellular and molecular investigation of the action of PMX..:

Mukherjee, A ; Huber, K ; Evans, H..
British Journal of Pharmacology.  151 (2007)  8 - p. 1167-1175 , 2007
Link: https://doi.org/10.1038/..
 
?
15

Determination of the antiangiogenesis agent 2-methoxyestrad..:

LAKHANI, N ; SPARREBOOM, A ; DAHUT, W..
Journal of Chromatography B.  806 (2004)  2 - p. 289-293 , 2004
Link: https://doi.org/10.1016/..
 
1-15